Lupin has informed that it enclosed a Press Release as regards, receipt of U.S. FDA approval for the Company’s Abbreviated New Drug Application for Varenicline Tablets, 0.5 mg and 1 mg, to market a generic equivalent of Chantix® Tablets, 0.5 mg and 1 mg, of PF Prism C.V.
The above information is a part of company’s filings submitted to BSE.